, on behalf of the Pediatric Acute Liver Failure Study Group* Objectives To assess the accuracy of blood lactate and lactate: pyruvate molar ratio (L:P) as a screen for mitochondrial, respiratory chain, or fatty acid oxidation disorders in children with pediatric acute liver failure (PALF); to determine whether serum lactate ≥ 2.5 mmol/L or L:P ≥ 25 correlated with biochemical variables of clinical severity; and to determine whether lactate or L:P is associated with clinical outcome at 21 days.
P ediatric acute liver failure (PALF) is a rare and potentially fatal illness caused by heterogeneous insults including infections, drugs and toxins, autoimmune liver disease, genetic/metabolic diseases, ischemia/reperfusion injury, and, in a relatively large proportion, a cause is not identified.
1 PALF continues to have a high rate of mortality and is the third leading indication in childhood for liver transplantation. 2 Primary mitochondrial disorders, including mitochondrial DNA (mtDNA) depletion syndromes, occur in 1 in 5000 live births and are a known cause of PALF in children <2 years of age. [3] [4] [5] One of the biochemical features suggestive of a mitochondrial disorder is a serum lactate concentration ≥ 2.5 mmol/L, especially in cases with respiratory chain alterations or mtDNA depletion syndrome. 6 Elevated blood lactate levels, however, can be caused by factors other than primary mitochondrial function, including poor collection technique, tissue hypoxia/ischemia, thiamine deficiency, or secondary mitochondrial dysfunction. 7, 8 Conversely, patients with certain mitochondrial diseases, such as DNA polymerase gamma (POLG1)-associated disease, MPV17 deficiency, Leber hereditary optic neuropathy, Leigh disease, Kearns-Sayre syndrome, and complex I deficiency, may have normal or minimally elevated lactate levels even in the setting of a metabolic crisis. 9 The lactate to pyruvate molar ratio (L:P) is proposed to be a better screening test for mitochondrial disorders, because the L:P reflects the equilibrium between the product and substrate of the reaction catalyzed by lactase dehydrogenase and indirectly reflects the NADH:NAD+ cytoplasmic redox state. 10 When cellular respiration or mitochondrial oxidative metabolism is impaired, such as in inborn errors of components of the mitochondrial respiratory chain, there is an increase in reducing equivalents (excess NADH and absence of NAD+) that results in an elevated L:P. In the past an L:P ≥ 25 has been considered to be highly suggestive of respiratory chain dysfunction 11 ; however, an elevated lactate or an elevated L:P also could represent secondary mitochondrial dysfunction occurring as a result of severe liver disease. Therefore, we sought to understand whether lactate and the L:P could be used to distinguish accurately primary mitochondrial causes of PALF. We also sought to determine whether elevated lactate and an elevated L:P represented more severe liver disease and thus predicted poor clinical outcomes.
The Mitochondrial Liver Diseases Working Group of the Childhood Liver Disease Research Network (ChiLDReN) recently recommended screening for mitochondrial disorders in infants and children with severe liver dysfunction, including those presenting with PALF, by examining for elevated blood lactate and the L:P
12
; however, the role and utility of these screening tests for mitochondrial disorders in patients with PALF have not been determined systematically. We hypothesized that an elevated serum lactate ≥ 2.5 mmol/L in combination with an elevated L:P ≥ 25 would identify patients with primary mitochondrial causes of PALF and that these elevated laboratory values early during the onset of PALF would be predictive of clinical outcomes. To address these hypotheses, we used the PALF Study Group dataset to (1) assess the accuracy of blood lactate and L:P as a screen for mitochondrial, respiratory chain, or fatty acid oxidation disorders in children with PALF; (2) determine whether serum lactate ≥ 2.5 mmol/L or L:P ≥ 25 correlated with biochemical variables that reflect clinical severity in children with PALF; and (3) determine whether lactate level or L:P is associated with clinical outcomes at 21 days in patients with PALF.
Methods
Data were obtained from the PALF Study Group registry, a National Institutes of Health-supported, multicenter, prospective study initiated in 1999 that collects data and specimens on children <18 years of age with PALF from 24 participating centers in the US, Canada, and the United Kingdom (ClinicalTrials.gov: NCT00986648). Definitions used and study methodology have been reported previously. 1, 13 The enrollment criteria for PALF required (1) the presence of severe hepatic dysfunction occurring within 8 weeks of onset of illness, (2) no known underlying chronic liver disease, and (3) a liverbased coagulopathy (not corrected with vitamin K) with an international normalized ratio (INR) ≥ 1.5 or prothrombin time ≥ 15 seconds in patients with encephalopathy or an INR ≥ 2.0 or prothrombin time ≥ 20 seconds in patients without encephalopathy. Enrollment occurred as soon as possible after hospital admission to the study site. The study protocol was approved by the individual centers' institutional review boards. Evaluation and management of each participant was based on local standard of care; however, the PALF study group had agreed-on guidelines for optimal evaluation of PALF at different ages.
1 Data collected by each site were transmitted to a central data-coordinating center for data editing and quality control procedures.
Participants in the PALF study dataset who had a serum lactate and pyruvate concentration obtained on the same day (within 7 days of study enrollment) were identified. Demographic information including sex, race, ethnicity, age at enrollment, was collected. Laboratory data used in this analysis included the following: the first serum lactate and pyruvate levels drawn on the same day, the resulting calculated L:P, and aspartate aminotransferase (AST), alanine transaminase (ALT), and INR drawn on the same day as the lactate and pyruvate levels. Minimum glucose during the first 7 days of enrollment also was used in analysis. Participants were classified into 3 diagnosis groups based on the final determination of the underlying etiology of PALF: (1) primary mitochondrial disease diagnosis, (2) other confirmed cause (eg, infectious, toxic or drug-induced [including acetaminophen], autoimmune, genetic, ischemia and others), and (3) indeterminate cause (no other etiology determined). For this analysis, the term primary mitochondrial disease includes subjects with a final diagnosis of mitochondrial, respiratory chain, or fatty acid oxidation disorders. Clinical outcome at 21 days (alive without liver transplant, death without transplant, or liver transplantation) was recorded for each participant.
Statistical Analyses
Descriptive statistics were used to characterize the participants by age at enrollment, sex, race, ethnicity, and baseline laboratory values. Because of a small sample size, the power to detect clinically meaningful differences between the 3 diagnosis groups is minimal; therefore, P values are not shown for the comparison among the 3 diagnostic categories. Spearman correlations were used to estimate the association between lactate, the L:P, and laboratory values within each diagnostic group. The exact Pearson c 2 test was used to determine whether the proportion of outcomes differed between the 2 lactate groups (<2.5 or ≥2.5) and the 2 L:P groups (ratio <25 or ≥25). All statistical analyses were performed with SAS 9.3 software (SAS Institute, Cary, North Carolina).
Results
For this study, data were analyzed for participants enrolled between December 27, 1999, and December 31, 2010. Of 986 participants in the PALF Study dataset, 537 had a serum lactate level recorded and, of these, 110 had both serum lactate and pyruvate drawn on the same day and were included in this analysis. The median time between hospital admission and enrollment in the PALF Study was 2 days (IQR 1-4 days). Likewise, the median time between hospital admission and lactate and pyruvate measurement was 2 days (IQR 1-4 days). Of these 110, 74 (67%) had a lactate level ≥ 2.5 mmol/L (Figure 1 ; available at www.jpeds.com). The median age at enrollment of these participants was 2.0 years (IQR 0.5-4.8 years), and 63 (57%) were male. Eight (7.3%) participants had a final diagnosis of a mitochondrial disorder, 37 (33.6%) had another confirmed diagnosis (other diagnosis group), and 65 (59.1%) had an indeterminate diagnosis. Of the 8 participants with a final diagnosis of mitochondrial disorder, 3 had mitochondrial disease, 3 had a respiratory chain disorder, and 2 had druginduced liver injury (nonacetaminophen) plus mitochondrial disease. Age, sex, race, and Hispanic ethnicity were similar among the 3 diagnosis groups ( Table I) . Baseline AST and ALT were lower in the mitochondrial diagnosis group.
Lactate, Pyruvate, and the L:P Were Similar in All Diagnostic Groups When we examined the distribution of lactate and pyruvate levels by diagnosis group, lactate tended to be greater in the mitochondrial disease group, but there was considerable overlap among the 3 groups (Figure 2) . Pyruvate values were comparable among the 3 groups (Figure 2 ). The L:P was elevated in subjects in all 3 groups (Figure 2 and Table I ). Surprisingly, only 25% (2/8) of the participants in the mitochondrial group had an elevated L:P (≥25), whereas 46% (17/37) in the other diagnosis group and 48% (31/65) in the indeterminate THE JOURNAL OF PEDIATRICS • www.jpeds.com Volume 182 diagnosis group had elevated L:P. We next examined the L:P as a function of serum lactate or pyruvate for each diagnosis group (Figure 3) . Lactate and L:P were correlated in all 3 diagnostic groups, with the strongest correlation being in the mitochondrial group (r = 0.81 P = .015), followed by the other diagnoses: (r = 0.62, P < .001), and indeterminate groups (r = 0.48, P < .001). Pyruvate levels did not correlate with L:P; thus, the blood lactate primarily was responsible for the elevation of L:P in individual subjects.
The Association between Lactate and L:P with Biochemical Variables That Reflect Clinical Severity in Children with PALF
We next examined the correlations between L:P and lactate level with ALT, AST, the AST/ALT ratio (a proposed indicator of mitochondrial injury), INR, and minimum glucose levels within each diagnostic group (Tables II and III; available at www.jpeds.com). No significant relationships of the L:P with any of these clinical variables were observed in any of the diagnosis groups. Lactate level was associated with INR in the other confirmed diagnosis group (r = 0.64, P < .001). The correlation coefficient in the mitochondrial group was similar in magnitude (0.54 for INR); however, the number of participants in the mitochondrial group was small and the correlations were not statistically different from zero.
Relationship between Lactate, L:P, and Clinical Outcome Finally, we examined the relationship between initial lactate and L:P with clinical outcomes (alive, death, or transplant) at 21 days after enrollment. Outcomes (Tables IV and V) did not differ significantly based on either lactate level (<2.5 or ≥2.5) or L:P (<25 or ≥25). We next examined clinical outcomes based on combination of lactate (<2.5 or ≥2.5 mmol/L) and L:P (<25 or ≥25). Outcomes were not significantly different among these 4 combinations (Tables IV and V).
Discussion
Establishing a diagnosis of a primary mitochondrial disorder in a patient who presents with PALF is of critical importance because it can impact prognosis and treatment choices, including the decision about whether to consider liver transplantation as a potential therapeutic option. Establishing the diagnosis, however, may be complicated and requires a high index of suspicion because children with mitochondrial disease can have heterogeneous clinical presentations with any combination of brain, muscle, heart, kidney and liver manifestations. This multicenter study evaluated the utility of the readily available serum lactate and the L:P as biomarkers to suggest a mitochondrial cause of PALF. We found that elevated serum lactate level and an elevated L:P relatively were common in all causes of PALF and were not specific for a mitochondrial etiology. In addition, there was no relationship between the L:P with biochemical indicators of the severity of liver injury or with clinical outcomes (alive, death, or liver transplantation). Thus, L:P appears to have limited clinical utility in children presenting with PALF. There are several possible explanations for the poor performance of serum lactate or L:P in distinguishing primary mitochondrial from other causes of PALF. First, it is possible that an underlying respiratory chain defect was present in a subset of participants who ultimately were diagnosed with another cause of PALF or were classified as indeterminate, perhaps increasing their susceptibility to or actually causing the liver failure. In this regard, Helbling et al 6 looked for mtDNA depletion in liver explants removed at the time of liver transplantation in 28 children with known nonmitochondrial chronic liver diseases and 45 with PALF (divided into those with viral, drug-induced, and unknown causes) compared with healthy controls and patients with known genetically confirmed mtDNA depletion. Levels of mtDNA were in the definite range of mtDNA depletion in 34% of the patients with PALF but in none of the patients with chronic liver disease. Furthermore, 7 of 43 (16%) patients with PALF vs 7 of 240 (3%) controls who underwent gene sequencing had single variants in mtDNA depletion genes (DGUOK or POLG) , suggesting that the heterozygote state for these gene variants may be a risk factor for PALF. Thus, elevated serum lactate level and L:P observed in many of our PALF study participants from all diagnosis groups may indicate underlying nondiagnosed gene variants causing or predisposing to mitochondrial dysfunction. 
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A second possible explanation for our findings is that nonmitochondrial-based liver injury may lead secondarily to reduced functioning of components of mitochondrial respiratory complexes causing altered redox status, culminating in elevated serum lactate and L:P in patients with PALF regardless of etiology. Supporting this secondary mitochondrial dysfunction hypothesis are recent data provided by Lane et al, 11 who used sophisticated techniques to assess mitochondrial function in end-stage liver disease. These investigators performed blue native polyacrylamide gel electrophoresis with immunodetection of respiratory chain complexes I-V, measured biochemical activity of respiratory chain complexes II and IV, and quantified mtDNA copy number in 45 explanted livers removed during transplantation. Abnormal mitochondrial function frequently was present in this cohort: 10 of 40 patients (25 %) had a defect of one or more respiratory chain enzyme complexes on blue native polyacrylamide gel electrophoresis, 20 patients (44%) had low activity of complex II and/ or IV, and 10 (22%) had a reduced mtDNA copy number. Importantly, combined respiratory chain deficiency and reduced amounts of mtDNA were detected in all 3 patients with PALF, none of whom had pathologic variants in DGUOK, POLG, or MPV17, the 3 most common genetic causes of mtDNA depletion and liver failure. All 6 patients diagnosed with liver tumors showed variable alterations in mitochondrial function. These authors concluded that mitochondrial dysfunction may occur secondary to a wide range of liver diseases of nonmitochondrial etiology, supporting secondary mitochondrial dysfunction as a cause of elevated lactate and L:P in our participants with PALF.
A final possible explanation for our findings is that the elevated lactate level and L:P were caused by altered fluid balance, hypotension, impaired tissue perfusion, hypoxia, or other factors that occur commonly in critically ill patients with PALF. Although classic teaching that an elevated L:P is characteristic of primary mitochondrial respiratory chain dysfunction and could be used to differentiate between primary mitochondrial dysfunction and these other causes, in fact, secondary altered cellular respiration can similarly elevate the L:P. There are several limitations to this study. First, there was no uniform standard procedure mandated in the PALF study for obtaining specimens for lactate and pyruvate; thus, there may be bias for which patients had these levels obtained. In addition, lactate levels artificially can be elevated if a patient is moving during phlebotomy or if there is prolonged use of a tourniquet when the blood sample is obtained. Likewise, pyruvate levels can be inaccurate if the blood sample is taken when the patient is postprandial or if the sample is not transferred immediately into 8% perchlorate on ice within 30 seconds of being drawn. 7, 8, 10 Each site in the PALF study, however, is a major pediatric center experienced in collecting specimens for clinical use of these tests. In addition, although spurious values of either lactate or pyruvate can affect the L:P, we expect that artificial elevation in L:P would have affected all 3 diagnosis groups uniformly.
The second limitation is that based on the design of the PALF study, follow-up information was only collected for 21 days after enrollment. Therefore, clinical outcome results beyond that time period were not available. The third limitation is that although this multicenter study is the largest study to date of L:P in PALF, the number of participants was relatively small (110 patients total, only 8 of whom had mitochondrial disorders) because only 11% of participants had same day determinations of lactate and pyruvate, limiting our power to detect significant correlations. In addition, there may be bias in terms of which subjects had lactate and pyruvate levels obtained based on clinical suspicion. The data from this study suggest that participants with PALF who were younger and white, and who had greater baseline AST/ALT ratios and INR, were more likely to have lactate and pyruvate measures drawn on the same day (Table VI; available at www.jpeds.com). Finally, the data from this study are only applicable to children with PALF and cannot be extrapolated to the diagnostic workup for mitochondrial disorders in other settings.
In summary, the findings of this study suggest that mitochondrial dysfunction reflected by serum lactate and the L:P is common in PALF. Although it is possible that a significant number of patients being diagnosed with indeterminate PALF truly have an undiagnosed primary mitochondrial disorder, it seems much more likely that secondary mitochondrial dysfunction occurs in a large number of patients with PALF independent of cause of acute liver failure. The data in this study clearly suggest that the diagnosis of a mitochondrial disorder and subsequent clinical decisions (including consideration for liver transplant) should not be based solely on blood lactate or the L:P. In the future, genetic testing that uses nextgeneration sequencing techniques (including whole-exome sequencing or targeted gene panels) with rapid turnaround may become available to identify quickly those children with a primary mitochondrial etiology of PALF. 
